Open AccessActivity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion
Author(s) -
Idoya Lahortiga,
Cem Akin,
Jan Cools,
Todd M. Wilson,
Nele Mentens,
Diane C. Arthur,
Irina Marić,
Pierre Noël,
Can Naci Kocabaş,
Peter Marynen,
Lawrence S. Lessin,
Iwona Włodarska,
Jamie Robyn,
Dean D. Metcalfe
Publication year - 2008
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.11836
Subject(s) - pdgfrb , imatinib , systemic mastocytosis , imatinib mesylate , fusion gene , basophilia , breakpoint , tyrosine kinase , cancer research , tyrosine kinase inhibitor , leukemia , medicine , biology , pathology , chromosomal translocation , immunology , genetics , bone marrow , receptor , myeloid leukemia , gene , cancer
Translocations involving region 5q31-32 (PDGFRB) have been reported in a variety of myeloproliferative diseases and are often associated with significant peripheral eosinophilia. We report an unusual case of a patient presenting with peripheral basophilia and systemic mastocytosis in whom cytogenetic analysis revealed a t(4;5)(q21.1;q31.3).